Plasma cfDNA and peripheral blood gDNA provide complementary information for molecular monitoring in myeloproliferative neoplasms.

Front Oncol · 2026 · PMC13065645 · PMID 41971416

Europe PMC DOI

hedged sentences

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

did not reach statistical significanceP = 0.090so close (0.05 < p ≤ 0.1)

Regarding spleen indices (spleen to body weight ratio), cfDNA exhibited a detectable, consistent association with disease burden (r = 0.443, P = 0.030; Figure 1G ), whereas the correlation observed for gDNA did not reach statistical significance (r = 0.353, P = 0.090; Figure 1H ).

also in 111,027 other papers

showed a trendno p-value reported

During treatment monitoring, cfDNA showed a trend toward higher sensitivity for resistance detection (25.6% vs. 17.9%), whereas gDNA appeared to be more sensitive for response confirmation (23.1% vs. 15.4%).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.